Intellectual Property and Other Litigation Risks
First written in FY2017. 7 of 8 entries say "Restated". Latest entry: FY2023-Q3.
111 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The company has disclosed that there have been no material changes regarding litigation risks involving intellectual property rights and other matters. - FY2020RestatedAnnual report
「Although we are focusing on establishing a compliance framework, we may receive claims for damages or face litigation from pharmaceutical companies and others on the grounds of patent or other infringements.」
The company continues to disclose litigation risks relating to intellectual property infringement, products, the environment, labor and other matters. - FY2019RestatedAnnual report
「Although we are focusing on establishing a compliance framework, we may receive claims for damages or face litigation from pharmaceutical companies and others on the grounds of patent or other infringements.」
The company continues to disclose litigation risks relating to intellectual property infringement, products, the environment, labor and other matters. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company has disclosed that there have been no material changes regarding litigation risks involving intellectual property rights and other matters. - FY2018RestatedAnnual report
「Although we are focusing on establishing a compliance framework, we may receive claims for damages or face litigation from pharmaceutical companies and others on the grounds of patent or other infringements.」
The company continues to disclose litigation risks relating to intellectual property infringement, products, the environment, labor and other matters. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding litigation risks involving intellectual property rights and other matters. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding litigation risks involving intellectual property rights and other matters. - FY2017First statedAnnual report
「Although we are focusing on establishing a compliance framework, we may receive claims for damages or face litigation from pharmaceutical companies and others on the grounds of patent or other infringements. We may also face litigation relating to products, the environment, labor and other matters.」
In addition to intellectual property infringement, litigation risks relating to products, the environment, labor and other matters have been disclosed comprehensively for the first time.